SirPAD Study Results to be Presented at VIVA 2026
New findings from the randomized SirPAD study on femoropopliteal arterial disease will be presented at VIVA 2026 in October. The study focuses on patients with claudication.
New results from the randomized SirPAD study will be presented at VIVA 2026, taking place from October 3–6 in Las Vegas. The presentations will concentrate on patients with femoropopliteal arterial occlusive disease, a condition often leading to claudication.
Femoropopliteal arterial disease involves blockages in the major arteries of the thigh and behind the knee. This condition restricts blood flow to the lower legs and feet, potentially causing pain during walking (claudication) and, in severe cases, critical limb ischemia.
The SirPAD study aims to evaluate the efficacy of various treatment strategies for this patient population. The findings presented at VIVA 2026 are expected to offer insights into the latest advancements in interventional cardiology and vascular surgery.
The VIVA conference is a prominent forum for vascular specialists to discuss the diagnosis, treatment, and emerging technologies in the management of vascular disease. The presentation of the SirPAD data is anticipated to provide valuable clinical information for healthcare providers.